By Ilan Zipkin
Staff Writer

Geron Corp.'s telomerase technology has been a discovery in search of therapeutic utility since the company was founded in 1992. The company began life focused on aging, and went public in July 1996 on the promise of its telomerase inhibition program to treat cancer. Neither idea has moved beyond the research stage.